Veröffentlichungen zur planB Studie
Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score® result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and –positive breast cancer patients.
Oleg Gluz, Ulrike Nitz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Stefan Kraemer, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Christer Svedman, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, and Nadia Harbeck.
Abstract | EBCC Vortrag
 
   
  
 
Veröffentlichungen zur ADAPT Studie
Substantial efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
Harbeck N, Gluz O, Christgen M, Braun M, Kümmel S, Potenberg J, Aktas B, Schumacher C, Forstbauer H, Augustin D, Krämer S, Just M, Tio J, Kleine-Tebbe A, Liedtke C, Kates RE, Hofmann D, Würstlein R, Kreipe H, Nitz U.
2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 506).
Abstract | Presentation | Video

Efficacy of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
Gluz O, Nitz U, Christgen M, Grischke E, Forstbauer H, Braun M, Warm M, Uleer C, Aktas B, Schumacher C, Hackmann J, Bangemann N, Staib P, Lindner C, Clemens M, Potenberg J, Thill M, Kohls A, Kümmel S, Perlova-Griff L, Liedtke C, Hofmann D, Kates RE, Würstlein R, Kreipe H, Harbeck N.
2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 1032).
Abstract | Poster

Luminal subtypes vs. early proliferation response and Oncotype DX® in early breast cancer: Observations from the WSG-ADAPT HR+/HER2- subprotocol.
Gluz, Nitz, Christgen , Kreipe, Kates, Kümmel, Braun, Schumacher, Würstlein, Harbeck on behalf of the ADAPT investigators.
14th St.Gallen International Breast Cancer Conference 2015, The Breast 24S1 (2015) S104–S105. 


Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate +/- endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial.
Gluz O, Nitz U, Kuemmel S, Kraemer S, Braun M, Schumacher C, Aktas B, Forstbauer H, Reimer T, Fasching P, Potenberg J, Hofmann D, Kates RE, Wuerstlein R, Christgen M, Kreipe H, Harbeck N.
San Antonio Breast Cancer Symposium 2014, Poster Presentation P4-15-01.

ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.
Nitz U, Gluz O, Von Schumann R, Hofmann D, Kates RE, Kuemmel S, Braun M, Schumacher C, Nuding B, Aktas B, Forstbauer H, Maass N, Rezai M, Kraemer S, Warm M, Wuerstlein R, Harbeck N.
San Antonio Breast Cancer Symposium 2014, Poster Presentation OT3-2-04.

Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multizentrischen Phase II/III WSG-ADAPT Studie.
Gluz O, Kümmel S, von Schumann R, Nuding B, Schumacher C, Maass N, Rezai M, Braun M, Aktas B, Forstbauer H, Kusche M, Krämer S, von der Assen A, Kreipe HH, Christgen M, Hofmann D, Kates RE, Shak S, Würstlein R, Nitz U, Harbeck N, on behalf of the ADAPT investigators.
34. Jahrestagung Deutsche Gesellschaft für Senologie 2014, Referenznummer: 42


Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multi-zentrischen Phase II/III WSG-ADAPT Studie.
Krauß K, Gluz O, Kümmel S, von Schumann R, Nuding B, Schumacher C, Maass N, Rezai M, Braun M, Aktas B, Forstbauer H, Kusche M, Krämer S, von der Assen A, Kreipe H, Christgen M, Hofmann D, Kates R, Shak S, Würstlein R, Nitz U, Harbeck N on behalf of the ADAPT investigators.
60. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2014, freier Vortrag Nummer FV-05.04.

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.
Oleg Gluz, Ulrike Nitz, Ronald Kates, Daniel Hofmann, Sherko Kümmel, Benno Nuding, Claudia Schumacher, Bahriye Aktas, Helmut Forstbauer, Nicolai Maass, Michael Wilhelm Braun, Mahdi Rezai, Manfred Kusche, Albert von der Assen, Steven Shak, Christer Svedman, Rachel Wuerstlein, Nadia Harbeck, Hans Heinrich Kreipe, Matthias Christgen.
2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 524^)
Abstract

Run-In Phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score® and conventional parameters in clinical routine.
Nadia Harbeck, Oleg Gluz, Daniel Hofmann, Hans H. Kreipe, Mathias Christgen, Christer Svedman, Steve Shak, Sherko Kümmel, Benno Nuding, Mahdi Rezai, Helmut Forstbauer, Rachel Würstlein, Ronald E. Kates, Ulrike Nitz.
31. Deutscher Krebskongress 2014, Abstract ID 455, Poster ID 455.

Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine
Harbeck N, Gluz O, Kreipe HH, Christgen M, Svedman C, Shak S, Hofmann D, Kuemmel S, Nuding B, Rezai M, Schumacher C, Kusche M, Forstbauer H, Maass N, Kraemer S, Aktas B, Mohrmann S, Wuerstlein R, Kates RE, Nitz U. 
San Antonio Breast Cancer Symposium 2013, P6-05-11
Abstract | Poster

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Daniel Hofmann, Ulrike Nitz, Oleg Gluz, Ronald E Kates, Timo Schinkoethe, Peter Staib, Nadia Harbeck.
Trials 2013, 14:261 (19 August 2013)
Abstract | Full text | PDF | PubMed

ADAPT - Adjuvante an Dynamischen Markern-Adjustierte Personalisierte Therapie Studie zur Therapie-Individualisierung beim frühem Mammakarzinom - erste Ergebnisse aus dem  HR+/HER2-  und HR+/HER2+ Subprotokoll.
Krauss K, Kuemmel S, Gluz O, Kreipe HH, Christgen M, Hofmann D, Kates RE, Nuding B, Rezai M, Kusche M, Schumacher C, Maass N, Nitz U, Harbeck N.
33. Jahrestagung der Deutschen Gesellschaft für Senologie, Referenznummer: 92


ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.
Nadia Harbeck, Daniel Hofmann, Oleg Gluz, Ronald E. Kates, Sherko Kümmel, Benno Nuding, Mahdi Rezai, Manfred Kusche, Claudia Schumacher, Ulrike Nitz
2013 ASCO Annual Meeting, Abstract No.: TPS655^
J Clin Oncol 31, 2013 (suppl; abstr TPS655^)
Abstract

ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy. A WSG trial optimizing risk assessment and therapy response prediction in early breast cancer.
Würstlein R, Gluz O, Hofmann D, Kates RE, Harbeck N, Nitz U.
2013 St. Gallen International Breast Cancer Conference, Poster No.: 152


ADAPT - Adjuvant Dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.

Gluz O, Hofmann D, Kates RE, Harbeck N, Nitz U.
San Antonio Breast Cancer Symposium 2012, Cancer Res December 15, 2012; 72(24 Supplement): OT3-3-02
Abstract
 
   
  
 
Veröffentlichungen zur WSG-BCIST (NanoString PAM50) Studie
Prospective Multicenter Decision Impact WSG-BCIST Study in Postmenopausal ER+ HER2- N0 Early Breast Cancer (EBC) supports molecular testing for intrinsic subtype definition.
Wuerstlein R, Sotlar K, Gluz O, Hofmann D, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Morel P, Cowens W, Hornberger J, Kates RE, Pelz E, Harbeck N.
2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 535).
Abstract | Poster


Prospective observational study of clinical outcomes for the NanoString® Technologies Prosigna™ test by the West German Study Group.
Wuerstlein R, Sotlar K, Otremba B, Gluz O, Pelz E, Hofmann D, Kates RE, Witzel I, Schindlbeck C, Janni W, Schem C, Tesch H, Harbeck N.
San Antonio Breast Cancer Symposium 2014, Poster Presentation OT3-2-03.


WSG-BCIST mit PAM50 - Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test.

Würstlein R, Harbeck N, Sotlar K, Pelz E, Otremba B, Witzel I, Janni W, Schindlbeck C, Schem C, Tesch H, Hofmann D, Kates RE, Gluz O.
DGGG 2014, Poster Nr. PO-Onko 10.02. 
 
   
  
 
Veröffentlichungen zur planB Studie

Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial.
von Schumann R, Gluz O, Nitz U, Clemens M, Lübbe K, Aktas B, Just M, Noesselt T, Henschen S, Hackmann J, Lorenz-Salehi F, Freese K, Svedman C, Kates RE, Kreipe H, Harbeck N, Liedtke C.
2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr e11555).

Abstract

Prognostic impact of discordance between different risk assessment tools in early breast cancer (Recurrence Score, Central Grade, Ki67): early outcome analysis from the prospective Phase III WSG-PlanB Trial.
Nitz U, Gluz O, Kates RE, Hofmann D, Kreipe HH, Christgen M, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Liedtke C, Würstlein R, Harbeck N.
San Antonio Breast Cancer Symposium 2014, Poster Presentation P4-11-01.


Febrile neutropenia (FN) and infections under adjuvant chemotherapy of breast cancer with 6 x TC vs. 4 x EC – 4 x Doc: Toxicity data of the WSG planB trial.
Oleg Gluz, Daniel Hofmann, Raquel Von Schumann, Ronald E. Kates, Michael Clemens, Marwa Salem, Toralf Reimer, Bernhard Liedtke, Bahriye Aktas, Andrea Stefek, Anke Pollmanns, Fatemeh Lorenz-Salehi, Christoph Uleer, Petra Krabisch, Doris Augustin, Nadia Harbeck, Ulrike Nitz.
60. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2014, Poster Presentation.


Febrile Neutropenien (FN) und Infektionen unter adjuvanter Chemotherapie des Mammakarzinoms mit 6xTC vs. 4xEC-4xDoc: Toxizitätsdaten der WSG planB Studie.
von Schumann R, Gluz O, Hofmann D, Kates RE, Clemens M, Salem M, Reimer T, Liedtke B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Augustin D, Harbeck N, Nitz U.
33. Jahrestagung der Deutschen Gesellschaft für Senologie, Referenznummer: 90


WSG plan-B trial: Comparison of recurrence score and definitions of luminal subtypes
Wuerstlein R, Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, Uleer C, Augustin D, Hofmann D, Thomssen C, Nitz U, Harbeck N.
2013 St. Gallen International Breast Cancer Conference, Poster No.: 151


Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB trial.

Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, Uleer C, Augustin D, Hofmann D, Thomssen C, Nitz U, Harbeck N.
San Antonio Breast Cancer Symposium 2012, Cancer Res December 15, 2012; 72(24 Supplement): P2-10-08 
Abstract


Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-planB trial.
San Antonio Breast Cancer Symposium 2011, S4-3
Abstract | Slides | Oral Presentation  Donnerstag, 8. Dezember - General Session 4

First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC)
San Antonio Breast Cancer Symposium 2011, P5-18-03
Abstract |
Poster

Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.
J Clin Oncol 2011, 29 suppl: abstr 10594
Abstract

WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.
J Clin Oncol 2010, 28 suppl: abstr TPS106^
Abstract

Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial.
San Antonio Breast Cancer Symposium 2010, P2-09-05
Abstract | Poster

Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer.
San Antonio Breast Cancer Symposium 2010, P3-10-12
Abstract | Poster
 
   
  
 
Veröffentlichungen zur MINDACT Studie
The EORTC 10041/BIG 03-04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual.
European Multidisciplinary Cancer Congress der European Cancer Organisation 2011, 10 LBA
Abstract
 
   
  
 
Veröffentlichungen zur ARAplus Studie
Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer
U. Nitz, O. Gluz, I. Zuna, C. Oberhoff, T. Reimer, C. Schumacher, J. Hackmann, M. Warm, C. Uleer, V. Runde, J. Dünnebacke, N. Belzl, D. Augustin, R.E. Kates, N. Harbeck, on behalf of the West German Study Group
Annals of Oncology, Volume 25, Issue 1, Pp. 75-80.
Abstract

Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial.

San Antonio Breast Cancer Symposium 2011, PD07-06
Abstract | Poster
 
   
  
 
Veröffentlichungen zur EC-Doc Studie

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.
Breast Cancer Res Treat. 2015 Feb 28.

PubMed | Breast Cancer Research and Treatment



Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.
Ann Oncol. 2014 Aug;25(8):1551-7.
PubMed | Annals of Oncology


The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial.
2013 ASCO Annual Meeting, Abstract No.: 1092
J Clin Oncol 31, 2013 (suppl; abstr 1092)


Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer - Results from the EC-Doc Trial.

San Antonio Breast Cancer Symposium 2011, P1-06-03
Poster

Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial.
J Clin Oncol (2011) 29 suppl: abstr 10625
Abstract

Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials.
J Clin Oncol (2011) 29 suppl: abstr 1021
Abstract

Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer- An Analysis of the WSG EC-Doc Trial.
San Antonio Breast Cancer Symposium 2010, P2-09-14
Poster
Abstract

 
   
  
 
VERÖFFENTLICHUNGEN DER WSG AM01 STUDIE

Prämiert mit dem ASCO Merit Award 2014
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.

Philip C. Schouten, Oleg Gluz, Nadia Harbeck, Svjetlana Mohrmann, Raihana Diallo-Danebrock, Enrico Pelz, Janneke Kruizinga, Arno Velds, Marja Nieuwland, Ron M. Kerkhoven, Cornelia Liedtke, Markus Frick, Ronald Kates, Sabine C. Linn, Ulrike Nitz, Frederik Marme.
J Clin Oncol 32:5s, 2014 (suppl; abstr 11018)
Abstract

Die Ergebnisse der ersten WSG Studie wurden in diesen Fachzeitschriften publiziert:

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Ann Oncol (2008) 19: 861-870
Abstract

Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy.
Clin Cancer Res (2007) 15: 488
Abstract

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
Lancet (2005) 366: 1935 - 1944
Abstract

 
   
  
 
WSG
WOMEN´S HEALTHCARE
STUDY GROUP

Ludwig-Weber-Straße 15b
41061 Mönchengladbach

FON + 49 (0) 2161. 5 66 23-0
FAX  + 49 (0) 2161. 5 66 23-19

wsg@wsg-online.com
www.wsg-online.com
 
   
  
 
Publiziert für Sie
FORUM_DKG-PRÄDIKTIVE_GENSIGNATUREN